Filing Flows › Recursion Pharmaceuticals (RXRX) › R&D spending
Recursion Pharmaceuticals (RXRX) R&D spending by quarter
Recursion Pharmaceuticals' R&D spending was $99.1M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $87.9M (Q1 2026) to $130M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $99.1M | +11% | -18% |
| Q2 2026 | $89.6M | +2% | -30% |
| Q1 2026 | $87.9M | -8% | -32% |
| Q4 2025 | $95.9M | -21% | — |
| Q3 2025 | $121M | -6% | — |
| Q2 2025 | $129M | -0.8% | — |
| Q1 2025 | $130M | — | — |
Q3 2026 at a glance
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Recursion Pharmaceuticals' R&D spending?
Recursion Pharmaceuticals' R&D spending was $99.1M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Recursion Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $87.9M (Q1 2026) to $130M (Q1 2025).
Q3 2026 results → · How Recursion Pharmaceuticals makes money →